By Senator Berman

26-01316-25 2025876

A bill to be entitled

An act relating to chimeric antigen receptor T-cell therapy; creating ss. 627.64198, 627.6614, and 641.31078, F.S.; prohibiting health insurers and health maintenance organizations issuing, delivering, or renewing certain policies or contracts from refusing to contract with or denying coverage for certain providers of chimeric antigen receptor T-cell therapy; providing an effective date.

Be It Enacted by the Legislature of the State of Florida:

Section 1. Section 627.64198, Florida Statutes, is created to read:

issuing, delivering, or renewing a health insurance policy in this state on or after January 1, 2026, which provides coverage for chimeric antigen receptor T-cell (CAR-T) therapy may not refuse to contract with or deny coverage for the administration of CAR-T therapy by any provider that qualifies as a certified health care facility under the Food and Drug Administration procedure for the CAR-T product license and that is included in the policy's provider network for any other service.

Section 2. Section 627.6614, Florida Statutes, is created to read:

627.6614 CAR-T therapy providers.—A health insurer issuing, delivering, or renewing a group health insurance policy in this state on or after January 1, 2026, which provides coverage for chimeric antigen receptor T-cell (CAR-T) therapy may not refuse

30

31

32

3334

35

36

37

38 39

40

41

42

43

44

45

46

47

26-01316-25 2025876

to contract with or deny coverage for the administration of CAR-T therapy by any provider that qualifies as a certified health care facility under the Food and Drug Administration procedure for the CAR-T product license and that is included in the policy's provider network for any other service.

Section 3. Section 641.31078, Florida Statutes, is created to read:

organization issuing, delivering, or renewing a health maintenance organization issuing, delivering, or renewing a health maintenance contract in this state on or after January 1, 2026, which provides coverage for chimeric antigen receptor T-cell (CAR-T) therapy may not refuse to contract with or deny coverage for the administration of CAR-T therapy by any provider that qualifies as a certified health care facility under the Food and Drug Administration procedure for the CAR-T product license and that is included in the policy's provider network for any other service.

Section 4. This act shall take effect January 1, 2026.